Skip to main content
Premium Trial:

Request an Annual Quote

GeneFormatics Acquires License For Scripps Tech

Premium

LA JOLLA, Calif.--GeneForm-atics has acquired exclusive worldwide technology rights for a group of protein function identification algorithms invented at the Scripps Research Institute. These proprietary methods will be used to provide biologically relevant structure-based function predictions for genomic sequences for GeneFormatics' pharmaceutical and agricultural clients.

GeneFormatics descriptors of enzyme active sites, called Fuzzy Functional Forms (FFFs), will provide informatics techniques that are faster, simpler, more sensitive, and more accurate than current methods, GeneFormatics officials claimed.

"FFFs offer a significant advantage over current methods for sequence analysis and function prediction such as global sequence alignment and local sequence motif identification," said Jacquelyn Fetrow, coinventor of the technology, chief scientific officer of the company, and a former Scripps scientist. "Most of these methods are limited by the extent of the similarity between sequences of unknown and known function with the result that these methods increasingly fail as the sequence identity diverges into and beyond the twilight zone of sequence identity," Fetrow added.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.